← Diabetes Connections | Type 1 Diabetes
Diabetes Connections | Type 1 Diabetes
In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more
00:10:43
Loading summary
Transcript5 lines
- [00:01]
A
Support for this episode comes from Omnipod. At one of our recent Mom's Night out events, the Omnipod team was on site asking moms about their experience with the OmniPod 5 automated insulin delivery system. It was so much fun and it was great to hear what the moms have to say. Here's what Angela, mom to Dominic, told us.
- [00:21]
B
My son is 10 years old and he uses an Omnipod 5. It's the only pump he has used since he was diagnosed. It's been a life changing piece of equipment for him to have and he's a competitive swimmer. He is able to keep it on in the pool and we don't have to worry about disconnecting. So we absolutely love Omnipod and it has really just made a big difference in his Life.
- [00:40]
A
Wanna try Omnipod 5 for yourself? Request a free Omnipod 5 starter kit today by visiting omnipod.com diabetesconnections Terms and conditions apply. Eligibility may vary. Hello and welcome to Diabetes Connections. I'm your host Sarah Stacey Sims. We aim to educate and inspire about diabetes with a focus on people who use insulin. This is one of our in the News episodes where we bring you the top diabetes stories and headlines happening now. A reminder as always that you can find the sources and links and a transcript and more information for every story mentioned here in the show. Notes I had a little break from travel but back on the road very soon. I'm going to be in Las Vegas this weekend. Who's there? I would love to see you. I'd love to meet you at the Breakthrough T1D Summit happening this Saturday. And I'm going to be hanging around Vegas for the weekend hoping to meet some fun people, do some cool stuff. I've been to Vegas a couple of times before. If you've got suggestions, if you're going to be there, let me know. I would love to say hi. And we also have two Club 1921 events. These are for healthcare providers and patient leaders. Club 1921 is our new standalone. It's a one night only dinner event. It is free. These next two events are happening in April. Coming up fast. Atlanta on April 15th, Philadelphia on April 22nd. Please head on over to the website to learn more. We've kind of spruced up the website when it comes to events cause we have so many of them. So please go over check that out under the Events tab. Our top story this week, Metformin may be linked to the slower progression of age related macular degeneration among people with diabetes who are older than 55. Those taking metformin had a 37% lower chance of developing intermediate AMD, age related macular degeneration over a five year period compared with individuals not using the medication. AMD is one of the leading causes of vision loss, These researchers say a clinical trial is the next step. A new study suggests people with type 1 may be nearly three times as likely to develop dementia compared to people without diabetes, people with type 2 roughly twice the risk. I know this made a lot of headlines over the last couple days, but it is important to note that this study found an association. It did not find proof of causation. A lot more research is needed here. Researchers in Japan say they've developed an insulin pill in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called dnpv, and this peptide helps to transport insulin through the small intestine, where protein drug absorption usually does not work out very well. The result was a rapid and significant drop in blood glucose as well as a sustained decrease. These researchers say they are optimistic about the findings, but they note the results in mice do not guarantee the same outcomes in humans. Lilly says its next generation obesity drug, ritatotride, cleared its first late stage trial on type 2 patients. The drug lowered A1C by an average of 1.7 to 2% across different doses at 40 weeks and helped patients lose an average of 16.8% of their weight. Lilly has yet to file for approval of the drug for obesity or for diabetes. They expect to report findings from additional phase 3 trials by the end of this year. Interestingly, the highest dose of Zepbound lowered a 1C more than retatrotride, according to Lilly's own studies. Retatratotride works on GLP1, GIP and glucagon rather than just one or two like existing treatments. We're going to learn a lot more about this medication in the months to come and hopefully I will learn to pronounce it better. The Mini Med Flex gets FDA approval this is a new design from the company formerly known as Medtronic Diabetes. It's about half the size of the MiniMed 780G, no screen. It is smartphone controlled and has the Smart Guard with meal detection technology. Press release says minimed Flex will support the company's newest sensor portfolio, including Simplera Sync and the Instinct sensor made by Abbott that's at launch. MiniMed Flex is cleared for people over the age of 7 with type 1 and for people over the age of 18 who have insulin requiring type 2. Lots of new information out of the recent ATTD conference, including ketone monitoring, stem cell updates, protein and exercise. We'll get into all of it right after this. Right back to our conversation. But first, Diabetes Connections is brought to you by dexcom. You've probably heard me say this before, but it's worth repeating. Dexcom G7 isn't just great tech, it's accessible. Dexcom is the number one covered CGM brand and most people pay $20 or less per month. Dexcom is also the leader in CGM connectivity, offering the most connected CGM systems connect to a wide range of compatible pumps, pens and health apps to create a setup that fits your life your way. For us, dexcom has made managing diabetes feel less overwhelming and more in control. Check out Dexcom.com or your local pharmacy to get started. Now back to the news and ATTD conference had lots of research presented few headlines here. New study from the UK shows ketone monitoring could significantly reduce DKA risks in people with type one and type two. This was a study from Abbott which recently submitted a continuous dual glucose ketone meter to the FDA for clearance. The first modified insulin producing cells are still working 14 months after transplant without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy. Same gene editing strategy with lab grown stem cell derived insulin producing cells. Protein looks like it helps avoid lows during exercise Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times. Researchers say the body's response to protein was rapid within 20 minutes, which suggests taking it close to the beginning of exercise could help prevent lows. More info about type 1 and GLP1 medications researchers at ATTD presented the results of a small seven month study assessing the effectiveness of semaglutide for people with type 1 and obesity. 36% of participants spent more than 70% of their time in range, less than 4% of time below range and lost more than 5% of their body weight compared to those not taking semaglutide. Other studies show that since 2020, prescriptions of GLP1 medication have grown exponentially for adults with type 1 between the ages of 18 and 85. Semaglutide is not approved for the treatment of type 1. Lots of talk at ATTD about fully closed loops. Camdiab unveiled theirs called Liberty, which the company says is the world's first fully closed loop commercial launch. CamDiab offers the FDA approved MyLife Cam APS FX app for automating insulin delivery in my life's insulin delivery pumps. That company used to be known as Ipsomed and you can use that system with the FreeStyle Libre 3, Libre 3 Plus and Dexcom G6 insulin. Reported data on a fully closed loop automated insulin delivery system in people with type 2 Insulet plans to start a pivotal study this year, aims to launch in 2028. Tandem is on a similar course. Last month on an earnings call, the CEO told investors that his team plans to start a pivotal trial this year to support a filing for next year and Medtronic disclosed the start of a pivotal trial of its Vivera fully closed loop algorithm. Lots more information on lots more studies and research presented at attd. I'm going to link up more information as always in the show notes and finally, congrats to all honored by the 2026 National Scientific and Healthcare Achievement Awards from the American Diabetes Association. Shout out to friends of the show and friends of mine, Diana Isaacs, who was named the 2026 Outstanding Educator in Diabetes, and to Corey Hood, who receives the Richard Rubin Award. Dr. Rubin was a pioneer in behavioral science committed to keeping the person with diabetes at the center of research and care. And that is in the news. If you like it, please share it. We will be back next week with a long format interview show again. Hello in advance to everybody I'm going to meet in Las Vegas. I'm really excited about this trip. Please reach out and say hi in advance. You can DM me or send me an email. I would love to make sure to meet as many people as I can in what's going to be a very short trip. Thanks to my editor John Buchenis from Audio Editing Solutions and thank you so much for listening. Good morning. I'm Stacey Sims. I'll see you back here soon. Until then, be kind to yourself. Diabetes Connections is a production of Stacey Sims Media. All rights reserved.
- [10:01]
B
All wrongs avenged.
- [10:08]
A
From the very beginning, they mean everything to you and that means you do anything for them, especially if they're at risk. So when it comes to type 1 diabetes, screen it like you mean it. Even if just one person in your family has type one, you're up to 15 times more likely to get it too. Screen it like you mean it, because one blood test could help you spot type 1 long before you need insulin. Talk to your doctor about how to screen for type 1 diabetes because the more you know, the more you can do. So don't wait. Visit screenfortype1.com to learn more. Again, that's screenfortype1.com.